Welcome to our dedicated page for P3 HEALTH PARTNERS SEC filings (Ticker: PIII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
P3 Health Partners Inc. filings document a public population health management company with Class A common stock and warrants referenced in Exchange Act reports. The company’s Forms 8-K report operating results, management services agreements under its Care Enablement Model, ACO management arrangements, amendments to unsecured promissory notes, and debt and preferred stock actions tied to capital structure and Nasdaq listing-compliance matters.
Proxy filings describe annual meeting procedures, stockholder voting mechanics and corporate governance matters. The filing record also covers material agreements involving subsidiaries, unregistered equity securities, charter and bylaw amendments, significant holder financing relationships, and disclosures connecting P3’s value-based care model to revenue, medical margin and operating performance.
P3 Health Partners Inc. filed an amended insider report showing a stock-based award to one of its directors and correcting the director’s post–reverse split holdings. The director received 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 at a grant price of $0 under the company’s 2021 Incentive Award Plan. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amended filing updates the number of Class A shares beneficially owned after the transaction to 6,331 shares, reflecting the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is expressly described as being made solely to correct this post–reverse split ownership figure.
P3 Health Partners Inc. director reported an equity grant and corrected prior share ownership figures. On 08/06/2025, the director received 2,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU represents one share of Class A common stock and will vest upon the earlier of the company’s 2026 annual stockholder meeting and the one-year anniversary of the grant date.
Following the update, the director is shown as beneficially owning 6,331 shares of Class A common stock directly. The amendment was filed to correct the number of securities beneficially owned after the company’s 1-for-50 reverse stock split, which became effective on April 11, 2025, and is limited to fixing that post-split share count.
P3 Health Partners Inc. reported Q3 2025 results showing lower losses but continued pressure on liquidity and debt. Operating revenue was $345.3 million versus $362.1 million a year ago, as capitated revenue made up 98.9% of total. Operating loss narrowed to $44.2 million from $107.0 million, helped by a $23.7 million premium deficiency reserve release. Net loss was $69.5 million, with $31.6 million attributable to the controlling interest.
Interest expense rose to $20.5 million in the quarter. Cash was $37.7 million and the working capital deficit was $288.3 million as of September 30, 2025. Management disclosed that substantial doubt exists about the ability to continue as a going concern. Debt increased, including high‑coupon related‑party notes and a term loan amended to a 15% rate after September 30, 2025, with maturity extended to September 30, 2027. Net cash used in operating activities was $65.5 million for the nine months.
Shares outstanding were 3,286,465 Class A and 3,919,124 Class V as of November 3, 2025. A 1‑for‑50 reverse stock split was effected on April 11, 2025.
P3 Health Partners Inc. (PIII) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company shared the news via an Item 2.02 current report and attached the press release as Exhibit 99.1.
The information is furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities or automatically incorporated into other filings.
P3 Health Partners (PIII) formed P3 Commonwealth Innovation MSO, LLC with Commonwealth Primary Care ACO to manage and coordinate services for their accountable care organizations. The MSO signed a Management Services Agreement to oversee shared services, financial management, compliance, data analytics, clinical integration, strategic planning, and related support.
The MSO’s management fee from each ACO equals liabilities the MSO assumes and satisfies for that ACO under governmental ACO programs, plus a fair market value margin. Beginning in 2026, the MSO will also receive a portion of each ACO’s net shared savings under the agreement. Distributions of available net cash flow follow ownership interests: P3 ACO holds 80% and CPC ACO holds 20%. Governance rests with a five‑member board, with three managers designated by P3 ACO and two by CPC ACO. After the three‑year anniversary, P3 ACO may cause redemption of CPC ACO’s MSO interest within 90 days; if not exercised, CPC ACO gains a redemption right.